Bioasis Technologies IncOver The Counter Market:BIOAFView on Canadian Exchange
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bioasis Technologies Inc | 7.9K | 0.0x | --- |
BioSyntech Inc | 1.2K | 0.0x | --- |
Nanobac Pharmaceuticals Inc | 250.0 | 0.0x | --- |
MetaStat Inc | 590.0 | 0.0x | --- |
HempAmericana Inc | 2.9K | --- | --- |
Stromacel Inc | 10.0 | 0.0x | --- |
Company Information
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
Contact Information
- Headquarters
- 157 Church Street, 19th FloorNEW HAVEN, CT, United States 06510
- Phone
- 203-533-7082
- Fax
- 604-278-8785
Executives
- Executive Chairman of the Board, President, Chief Executive Officer
- Deborah Rathjen
- Chief Financial Officer
- David Jenkins
- Non-Executive Director
- John Hemeon
- Non-Executive Independent Director
- John Curran
- Non-Executive Independent Director
- Mario Saltarelli
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9K |
|---|---|
Revenue (TTM) | $192.8K |
Shares Outstanding | 79.4M |
Bioasis Technologies Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.03 |
Book Value | $-0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,141.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
